zolpidem has been researched along with Dementia in 8 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluate the effects of zolpidem use to develop dementia or Alzheimer disease from the Taiwan National Health Insurance Research Database (NHIRD)." | 7.81 | An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study. ( Chang, CM; Chi, CH; Hsu, HC; Kao, CH; Lin, CC; Shih, HI; Tu, YF, 2015) |
| " Pitolisant, a novel histamine-3 receptor antagonist/inverse agonist, gained approval for the treatment of excessive daytime sleepiness in adults with narcolepsy as well as obstructive sleep apnea." | 5.05 | New pharmacologic agents for insomnia and hypersomnia. ( Earl, DC; Van Tyle, KM, 2020) |
| "Sleep disturbance is common in dementia and often treated with Z-drugs (zopiclone, zaleplon, and zolpidem)." | 3.96 | Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. ( Aldus, C; Arthur, A; Ballard, C; Boyd, PJ; Fox, C; Howard, R; Loke, YK; Maidment, I; Richardson, K; Savva, GM; Steel, N, 2020) |
| "We evaluate the effects of zolpidem use to develop dementia or Alzheimer disease from the Taiwan National Health Insurance Research Database (NHIRD)." | 3.81 | An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study. ( Chang, CM; Chi, CH; Hsu, HC; Kao, CH; Lin, CC; Shih, HI; Tu, YF, 2015) |
| "Zolpidem was well tolerated with no withdrawal symptoms during the second 7-day placebo treatment period." | 2.67 | A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. ( Coquelin, JP; Curson, H; Shaw, SH, 1992) |
| "The prevalence of insomnia increases with age and affects up to 35% of community-dwelling adults with dementia." | 2.45 | Non-pharmacologic treatment of insomnia in persons with dementia. ( Darvishi, R; Kunik, ME; Shub, D, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Yoon, K | 1 |
| Kim, JT | 1 |
| Kwack, WG | 1 |
| Kim, D | 1 |
| Lee, KT | 1 |
| Yang, S | 1 |
| Lee, S | 1 |
| Choi, YJ | 1 |
| Chung, EK | 1 |
| Earl, DC | 1 |
| Van Tyle, KM | 1 |
| Richardson, K | 1 |
| Loke, YK | 1 |
| Fox, C | 1 |
| Maidment, I | 1 |
| Howard, R | 1 |
| Steel, N | 1 |
| Arthur, A | 1 |
| Boyd, PJ | 1 |
| Aldus, C | 1 |
| Ballard, C | 1 |
| Savva, GM | 1 |
| Shih, HI | 1 |
| Lin, CC | 1 |
| Tu, YF | 1 |
| Chang, CM | 1 |
| Hsu, HC | 1 |
| Chi, CH | 1 |
| Kao, CH | 1 |
| Shub, D | 1 |
| Darvishi, R | 1 |
| Kunik, ME | 1 |
| Jarry, C | 1 |
| Fontenas, JP | 1 |
| Jonville-Béra, AP | 1 |
| Autret-Leca, E | 1 |
| Cotroneo, A | 1 |
| Gareri, P | 1 |
| Nicoletti, N | 1 |
| Lacava, R | 1 |
| Grassone, D | 1 |
| Maina, E | 1 |
| De Sarro, G | 1 |
| Cabodi, S | 1 |
| Shaw, SH | 1 |
| Curson, H | 1 |
| Coquelin, JP | 1 |
2 reviews available for zolpidem and Dementia
| Article | Year |
|---|---|
New pharmacologic agents for insomnia and hypersomnia.
Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans; | 2020 |
Non-pharmacologic treatment of insomnia in persons with dementia.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antidepressive Agents, Tricyclic; Circadian Rhyth | 2009 |
1 trial available for zolpidem and Dementia
| Article | Year |
|---|---|
A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients.
Topics: Aged; Dementia; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; H | 1992 |
5 other studies available for zolpidem and Dementia
| Article | Year |
|---|---|
Potentially Inappropriate Medication Use in Patients with Dementia.
Topics: Aged; Benzodiazepines; Cholinergic Antagonists; Dementia; Female; Histamine; Humans; Inappropriate P | 2022 |
Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study.
Topics: Acetamides; Aged, 80 and over; Azabicyclo Compounds; Cohort Studies; Dementia; Female; Humans; Male; | 2020 |
An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Comorbidity; Dementia; Dose-Respon | 2015 |
Beneficial effect of zolpidem for dementia.
Topics: Dementia; Female; Humans; Hypnotics and Sedatives; Middle Aged; Pyridines; Zolpidem | 2002 |
Effectiveness and safety of hypnotic drugs in the treatment of insomnia in over 70-year old people.
Topics: Aged; Cognition Disorders; Dementia; Depression; Drug Administration Schedule; Female; Health Status | 2007 |